Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.

Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M.

Nat Med. 2012 Mar 4;18(4):529-37. doi: 10.1038/nm.2645.

PMID:
22388088
2.

New insights into signalling networks regulating breast cancer stem cells.

Swarbrick A, Daly RJ.

Breast Cancer Res. 2012 Sep 21;14(5):321. doi: 10.1186/bcr3209.

3.

Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.

Wang HC, Chiang WF, Huang HH, Shen YY, Chiang HC.

BMC Cancer. 2014 Jun 16;14:442. doi: 10.1186/1471-2407-14-442.

4.

A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.

Patel Y, Shah N, Lee JS, Markoutsa E, Jie C, Liu S, Botbyl R, Reisman D, Xu P, Chen H.

Oncotarget. 2016 Apr 5;7(14):18295-308. doi: 10.18632/oncotarget.7577.

5.

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.

Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J.

Oncogene. 2012 Sep 27;31(39):4266-78. doi: 10.1038/onc.2011.599. Epub 2012 Jan 16.

PMID:
22249265
6.

Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.

Su CM, Lee WH, Wu AT, Lin YK, Wang LS, Wu CH, Yeh CT.

J Nutr Biochem. 2015 Jun;26(6):675-85. doi: 10.1016/j.jnutbio.2015.01.005. Epub 2015 Mar 6.

PMID:
25792283
7.

Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.

Zhou X, Agazie YM.

J Biol Chem. 2009 May 1;284(18):12226-34. doi: 10.1074/jbc.M900020200. Epub 2009 Mar 4.

8.

The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A.

Oncogene. 2007 Oct 25;26(49):6979-88. Epub 2007 May 7.

9.

SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.

Zhang L, Zhang W, Li Y, Alvarez A, Li Z, Wang Y, Song L, Lv D, Nakano I, Hu B, Cheng SY, Feng H.

Oncogene. 2016 Oct 27;35(43):5641-5652. doi: 10.1038/onc.2016.100. Epub 2016 Apr 4.

10.

Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.

Jiang X, Guo H, Wu J, He Q, Li Y, Wang M, Pan H, Li W, Wang J, Wang Q, Shen J, Ke Y, Zhou R.

Haematologica. 2014 Dec;99(12):1834-45. doi: 10.3324/haematol.2014.106401. Epub 2014 Sep 5.

11.

Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.

Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NP, Pinto C, Soo ET, van Denderen BJ, Hill P, Ramsay RG, Sarcevic B, Newgreen DF, Thompson EW.

Breast Cancer Res. 2013 Nov 27;15(6):R113. doi: 10.1186/bcr3580.

12.

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.

Matalkah F, Martin E, Zhao H, Agazie YM.

Breast Cancer Res. 2016 Jan 4;18(1):2. doi: 10.1186/s13058-015-0659-z.

13.
14.

Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer.

Werner S, Frey S, Riethdorf S, Schulze C, Alawi M, Kling L, Vafaizadeh V, Sauter G, Terracciano L, Schumacher U, Pantel K, Assmann V.

J Biol Chem. 2013 Aug 9;288(32):22993-3008. doi: 10.1074/jbc.M113.456293. Epub 2013 Jun 29.

15.

Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.

Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu BC, Chen YW, Huang PI, Lo WL.

Oral Oncol. 2013 Jan;49(1):34-41. doi: 10.1016/j.oraloncology.2012.07.012. Epub 2012 Aug 11.

PMID:
22892238
16.

Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.

Bjorge JD, Pang AS, Funnell M, Chen KY, Diaz R, Magliocco AM, Fujita DJ.

PLoS One. 2011 Apr 26;6(4):e19309. doi: 10.1371/journal.pone.0019309.

17.

Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.

Sausgruber N, Coissieux MM, Britschgi A, Wyckoff J, Aceto N, Leroy C, Stadler MB, Voshol H, Bonenfant D, Bentires-Alj M.

Oncogene. 2015 Apr 23;34(17):2272-8. doi: 10.1038/onc.2014.170. Epub 2014 Jun 16.

PMID:
24931162
18.

SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.

Li S, Wang L, Zhao Q, Liu Y, He L, Xu Q, Sun X, Teng L, Cheng H, Ke Y.

J Biol Chem. 2014 Dec 5;289(49):34152-60. doi: 10.1074/jbc.M113.546077. Epub 2014 Oct 20.

19.

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.

Cicchini M, Chakrabarti R, Kongara S, Price S, Nahar R, Lozy F, Zhong H, Vazquez A, Kang Y, Karantza V.

Autophagy. 2014;10(11):2036-52. doi: 10.4161/auto.34398. Epub 2014 Oct 30.

20.

SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.

McPherson VA, Sharma N, Everingham S, Smith J, Zhu HH, Feng GS, Craig AW.

J Immunol. 2009 Oct 15;183(8):4940-7. doi: 10.4049/jimmunol.0900702. Epub 2009 Sep 28.

Supplemental Content

Support Center